Anti-interleukin-1 therapy in the management of gout

Current Rheumatology Reports

Volumn 16, Issue 2, 2014, Pages

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anakinra; Anti interleukin 1; Canakinumab; Gout; Management; Rilonacept; Therapy

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE ACETONIDE; ANTIGOUT AGENT; CARRIER PROTEIN; HYBRID PROTEIN; INFLAMMASOME; MONOCLONAL ANTIBODY; NLRP3 PROTEIN, HUMAN;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; GOUT; HUMAN; MONOTHERAPY; NONHUMAN; SINGLE DRUG DOSE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; GOUT; GOUT SUPPRESSANTS; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS;

EID: 84896700469     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0398-z     Document Type: Article

References (22)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10): 3136-41.
2. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. This is an excellent paper addressing much needed information about comorbidities in gout and how they affect prescriptions.
3. Chen CJ, Shi Y, Hearn A, FitzgeraldK,Golenbock D, Reed G, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262-71.
4. Di Giovine FS, Malawista SE, Nuki G, DuffGW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal- induced IL-1. J Immunol. 1987;138:3213-8.
5. Martinon F, PetrilliV, MayorA, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41.
6. Cronstein RN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8 Suppl 1:S3.
7. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2): R28.
8. Cho M, Ghosh P, Hans G, Rhiannon J, Gardner GC, Simkin PA. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum. 2010;60(9, Supplement): S163.
9. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210-4.
10. Ottaviani S, Moltò A, Ea H-K, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15:R123.
11. propertieshttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails.
12. Kapur S, BonkME. Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes. P T. 2009;34(3):138-41.
13. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HSB, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15(1):R25.
14. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in the treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613-7.
15. Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebocontrolled trial. Rheumatology. 2013;52(7):1285-92.
16. Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. Arthritis Rheum. 2012;64(3): 876-84.
17. So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for treatment of acute flares in refractory gouty arthritis. Arthritis Rheum. 2010;62(10):3064-74. PA.
18. Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53.
19. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264-71.
20. Schlesinger N, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their extensions. Ann Rheum Dis. 2012;71:1839-48.
21. de La Mata Llord J, Gonzalez Crespo R, Maese Manzano J. Treatment of rheumatoid arthritis with anakinra: a systematic review. Reumatol Clin. 2007;3(4):153-8.
22. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25-32.